SecBot SecBot
8-K ·Filed Jun 29, 2026

BCRX

BIOCRYST PHARMACEUTICALS INC
NEUTRAL
Impact 5/10
Horizonmonths Processed4mo ago SEC0001171843-26-004333
8-K material event: Items 2.05
Actionable Insight • Neutral

The restructuring is a capital-efficiency move that cuts costs and signals a pivot to external pipeline building, but comes with execution risk on finding external assets. Key catalysts ahead are navenibart Phase 3 data (Q3 2027) and BCX17725 proof-of-concept (year-end 2026). Watch for the amended 8-K detailing restructuring charges. The resolved ORLADEYO oral pellet delay removes a near-term overhang.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

BCRX drug pipeline →

navenibart

◆ Mixed Named in this 8-K
Impact
Phase
Phase 3
Time to market
Assuming positive Phase 3 data (Q3 2027), a US regulatory filing would follow around end-2027, with potential approval in 2028-2029.
Next catalyst
None dated

What to watchNavenibart is a promising long-term pipeline story within BioCryst, but there is no imminent binary catalyst for ~12+ months. Investors should watch for interim data updates at medical conferences and the pivotal Phase 3 ALPHA-ORBIT readout in Q3 2027. In the meantime, near-term BCRX value is driven by ORLADEYO commercial execution and the ongoing business restructuring.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$9.55
T+0 close · Jun 29, 2026 · via day close
Latest settled
−8.06%
T+60 · $8.78
Vs SPY
−12.45%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 29 $9.55entry
  2. T+1 · 5mo ago +4.71%α +3.93% · $10.00
  3. T+5 · 4mo ago +6.49%α +5.10% · $10.17
  4. T+20 · 4mo ago −2.20%α −1.92% · $9.34
  5. T+60 · 8w ago −8.06%α −12.45% · $8.78
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioCryst is discontinuing its internal discovery programs and closing its Birmingham, Alabama research facility by year-end 2026, shifting to an external innovation model. The restructuring lowers 2026 non-GAAP operating expense guidance by $30M to $420-440M, while revenue guidance of $635-660M is reaffirmed. Phase 3 ALPHA-ORBIT enrollment for navenibart is complete with top-line data expected in Q3 2027, and the manufacturing delay for ORLADEYO oral pellets is resolved with availability in early August.

Key Facts

  • Board approved plan to discontinue internal discovery programs and close Birmingham Discovery Center of Excellence facility by end of 2026.
  • Restructuring costs (contract termination, lease termination, severance, etc.) are not yet estimable; an amended 8-K will be filed when determined.
  • 2026 non-GAAP operating expense guidance reduced from $450-470M to $420-440M.
  • 2026 ORLADEYO revenue guidance reaffirmed at $625-645M; total company revenue guidance reaffirmed at $635-660M.
  • Phase 3 ALPHA-ORBIT for navenibart (HAE) enrollment completed; top-line 6- and 12-month efficacy data expected Q3 2027.
  • Phase 1 Part 4 study for BCX17725 (Netherton syndrome) dosing ongoing; proof-of-concept data expected by year-end 2026.
  • Previously disclosed manufacturing delay of ORLADEYO oral pellets resolved; product expected available early August 2026.

Financial Impact

Operating expense guidance lowered by $30M (from $450-470M to $420-440M). Revenue guidance unchanged at $635-660M total; $625-645M ORLADEYO. Restructuring costs TBD.

non-GAAP operating expenserevenue

Risk Factors

  • Restructuring costs and employee severance have not been quantified, unexpected high charges could pressure margins.
  • Shift to external innovation introduces dependency on in-licensing/partnership execution; internal pipeline optionality is eliminated.
  • Navenibart Phase 3 data is not expected until Q3 2027, leaving a long catalyst-free window.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001171843-26-004333
Exhibit: exh_991.htm0001171843-26-004333
Document: 0001171843-26-004333-index-headers.html0001171843-26-004333
Document: 0001171843-26-004333-index.html0001171843-26-004333
Document: 0001171843-26-004333.txt0001171843-26-004333

Track record

20 reports on BCRX

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.01% at T+20 after the Feb 26, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.71 Now $7.45 −3.35% settles Feb 16
  2. Nov 13, 20263d ago Press Release Neutral 3/10 Entry $7.61 Now $7.45 −2.10% settles Feb 11
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.53 Now $7.45 −1.06% settles Feb 8
  4. Nov 4, 202612d ago 8-K Bullish 6/10 No price data
  5. Nov 4, 202612d ago Press Release Bullish 6/10 Entry $8.24 Now $7.45 −9.59% settles Feb 2
  6. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $8.57 Now $7.45 −13.07% settles Feb 1
  7. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $8.37 Now $7.45 −10.99% settles Jan 26
  8. Oct 21, 202626d ago Press Release Neutral 1/10 Entry $7.78 Now $7.45 −4.24% settles Jan 20
  9. Aug 5, 202614w ago 8-K Bullish 7/10 Entry $9.07 to $8.46 Now $7.45 −17.86% ▼ −6.73% −6.92% vs SPY
  10. Jun 29, 202620w ago 8-K Neutral 5/10 Viewing Entry $9.55 to $8.78 Now $7.45 −21.99% ▼ −8.06% −12.45% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 3, 2026